Related Experiment Videos
Use of ACE Inhibitors for Secondary Prevention
Eric Larose1, Jean-Claude Tardif, Martial G. Bourassa
1Department of Medicine and Research Center, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec H1T 1C8, Canada. bourassa@icm.umontreal.ca
Insights
Angiotensin-converting enzyme (ACE) inhibitors significantly reduce mortality and cardiovascular events in patients with heart failure and after myocardial infarction. These drugs improve cardiovascular function and remodeling, warranting early and indefinite use in high-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- The renin-angiotensin system regulates blood pressure and fluid balance.
- Angiotensin-converting enzyme (ACE) inhibition has demonstrated significant benefits in cardiovascular conditions.
Purpose of the Study:
- To review the established role of ACE inhibitors in managing cardiovascular diseases.
- To provide evidence-based recommendations for ACE inhibitor use in specific patient populations.
Main Methods:
- Review of existing clinical trial data and evidence.
- Analysis of the impact of ACE inhibition on mortality, heart failure progression, and cardiovascular events.
Main Results:
- ACE inhibitors are recommended for symptomatic congestive heart failure (CHF) and asymptomatic patients with left ventricular ejection fraction <35-40%.
- Early initiation and indefinite therapy are suggested for acute myocardial infarction survivors and high-risk individuals (e.g., diabetics with risk factors, known vascular disease).
- ACE inhibition improves oxidative stress, endothelial function, ventricular remodeling, and reduces carotid artery thickening.
Conclusions:
- ACE inhibitors are crucial for managing CHF, post-myocardial infarction, and high-risk cardiovascular patients.
- Indefinite therapy is recommended for most patients benefiting from ACE inhibition.
- Current evidence does not support routine ACE inhibitor use post-coronary revascularization solely for preventing restenosis or graft disease.
Abstract:
The role of the renin-angiotensin system as a regulator of blood pressure, body fluids, electrolytes, and neurohormonal activation has been established for more than two decades. The dramatic benefits of angiotensin-converting enzyme (ACE) inhibition on overall mortality, progression to heart failure, and major cardiovascular events were first demonstrated in patients with congestive heart failure (CHF) or left ventricular dysfunction. ACE inhibitors should be prescribed for all patients with symptomatic CHF and for all asymptomatic patients with a left ventricular ejection fraction less than 35% to 40%, unless contraindicated or not tolerated, and therapy should be continued indefinitely. Data have shown that ACE inhibition improves oxidative stress, endothelial and ventricular function, and reduces ventricular remodeling as well as progression of carotid intimal and medial thickening. Current evidence suggests that ACE inhibitors should be prescribed as early as possible for all patients with acute myocardial infarction, unless contraindicated or not tolerated, and that they should be continued for at least 6 weeks; moreover, because these patients automatically qualify as high-risk individuals, indefinite therapy should be considered. Likewise, individuals at increased risk for major cardiovascular events (diabetic patients with additional risk factors and patients with known vascular disease) should be prescribed ACE inhibitors, unless contraindicated or not tolerated, and therapy should be continued indefinitely. There is not sufficient evidence at present to recommend the use of ACE inhibitors after coronary revascularization for the specific goal of preventing restenosis or graft disease, in the absence of decreased ejection fraction, CHF, or a new myocardial infarction.